Roche bispecific t-cell engager improves survival in lymphoma, teeing up label expansion
Roche said Monday that its bispecific T-cell engager Columvi improved survival in a Phase III lymphoma trial, clearing the drugmaker to seek a full, expanded label that could drive sales growth.